Suppr超能文献

青春期前后性别焦虑的儿童:青春期抑制及治疗模式

The peripubertal gender-dysphoric child: puberty suppression and treatment paradigms.

作者信息

Olson Johanna, Garofalo Robert

出版信息

Pediatr Ann. 2014 Jun;43(6):e132-7. doi: 10.3928/00904481-20140522-08.

Abstract

Gender-nonconforming youth are emerging at increasingly younger ages, and those experiencing gender dysphoria are seeking medical care at, or sometimes even before, the onset of puberty. Youth with gender dysphoria are at high risk for depression, anxiety, isolation, self-harm, and suicidality at the onset of a puberty that feels wrong. Medical providers would benefit from understanding interventions that help gender-nonconforming children and youth thrive. The use of gonadotropin-releasing hormone (GnRH) agonists to block the onset of an undesired puberty in youth with gender dysphoria is a relatively new practice, particularly in the United States. These medications shut down the hypothalamic-pituitary-gonadal axis (HPG), and the production of either testosterone or estrogen is temporarily halted. Puberty blocking allows a young person to explore gender and participate more fully in the mental health therapy process without being consumed by the fear of an impending developmental process that will result in the acquisition of undesired secondary sexual characteristics. GnRH agonists have been used safely for decades in children with other medical conditions, including central precocious puberty. Potential side effects of GnRH agonists include diminished bone density, injection site problems, emotional instability, and weight gain. Preliminary data have shown GnRH agonists to be very helpful in improving behavioral and overall functioning outcomes. Puberty suppression should ideally begin in the first stages of pubertal development and can be given via intramuscular or subcutaneous injections, or via an implant that is inserted in the upper arm. Monitoring to assure suppression of the HPG axis should occur regularly. Gender-nonconforming youth who remain gender dysphoric can go on to receive cross-sex hormones for phenotypic gender transition when they are older. GnRH agonists have changed the landscape of medical intervention for youth with gender dysphoria and are rapidly becoming the standard of practice.

摘要

性别不一致的青少年出现的年龄越来越小,那些经历性别焦虑的青少年在青春期开始时甚至有时在青春期开始之前就寻求医疗护理。患有性别焦虑的青少年在感觉不对的青春期开始时,面临着抑郁、焦虑、孤独、自我伤害和自杀的高风险。医疗服务提供者若能了解有助于性别不一致的儿童和青少年茁壮成长的干预措施,将受益匪浅。使用促性腺激素释放激素(GnRH)激动剂来阻止患有性别焦虑的青少年出现不期望的青春期,这是一种相对较新的做法,尤其是在美国。这些药物会关闭下丘脑 - 垂体 - 性腺轴(HPG),睾酮或雌激素的分泌会暂时停止。青春期阻断使年轻人能够探索性别,并更充分地参与心理健康治疗过程,而不会被对即将到来的发育过程的恐惧所困扰,因为这个过程会导致出现不期望的第二性征。GnRH激动剂已在患有其他疾病的儿童中安全使用了数十年,包括中枢性性早熟。GnRH激动剂的潜在副作用包括骨密度降低、注射部位问题、情绪不稳定和体重增加。初步数据表明,GnRH激动剂在改善行为和整体功能结果方面非常有帮助。青春期抑制理想情况下应在青春期发育的第一阶段开始,可以通过肌肉注射或皮下注射,或通过插入上臂的植入物给药。应定期进行监测,以确保HPG轴被抑制。仍然存在性别焦虑的性别不一致的青少年长大后可以继续接受跨性别激素进行表型性别转换。GnRH激动剂改变了对患有性别焦虑的青少年的医疗干预局面,并正迅速成为标准做法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验